Related Experiment Video
Updated: Jun 14, 2025

Author Spotlight: Quantitative Detection of DNA Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in
Yibo Luo1, Himadri Biswas1, Yetunde Makinwa1
1Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA.
Abstract:
DNA damage-based drugs are widely used in cancer therapy, yet resistance remains a major challenge. In this study, we uncovered a non-DNA repair mechanism contributing to resistance in pancreatic ductal adenocarcinoma (PDAC). We show that in gemcitabine-resistant PDAC cells, CIP2A undergoes ubiquitin-mediated degradation, resulting in enhanced PP2A phosphatase activity. This leads to the dephosphorylation of ATR at Ser428 in the cytoplasm, promoting the formation of the prolyl cis-isomeric form of ATR at its Ser428-Pro429 motif. The resulting cis-ATR functions as a mitochondria-targeted antiapoptotic protein (mtATR). Surprisingly, resistant PDAC cells paradoxically accumulated both mtATR and proapoptotic tBid at the mitochondria, forming a stable mtATR-tBid complex that induces a state of apoptotic dormancy. Disrupting this complex, either with the PP2A inhibitor LB-100 or a cytoplasmic ATR-specific antibody, reactivates the pre-accumulated tBid and restores apoptosis in resistant PDAC cells. In an orthotopic PDAC mouse model, LB-100 alone significantly inhibit gemcitabine-resistant tumor growth by disrupting the mtATR-tBid complex. These findings reveal a previously unrecognized mechanism of resistance to DNA damage-based therapies and identify a novel action mechanism of LB-100, characterized by the CIP2A degradation-mediated PP2A-mtATR-tBid axis. By targeting mtATR-tBid-mediated apoptotic dormancy, this strategy offers a promising approach to restore apoptotic sensitivity in drug-resistant cancers.
Insights
Researchers discovered a new way cancer cells resist chemotherapy. In pancreatic cancer, a protein complex (mtATR-tBid) stops cell death. Inhibiting this complex restores chemotherapy effectiveness against resistant tumors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chemotherapy resistance is a major obstacle in cancer treatment, particularly for DNA damage-based drugs like gemcitabine.
- Pancreatic ductal adenocarcinoma (PDAC) frequently develops resistance, necessitating novel therapeutic strategies.
- Understanding non-DNA repair mechanisms of resistance is crucial for overcoming treatment failure.
Purpose of the Study:
- To elucidate a novel non-DNA repair mechanism driving gemcitabine resistance in PDAC.
- To identify therapeutic targets that can restore sensitivity to DNA damage-based chemotherapy.
- To investigate the role of the CIP2A-PP2A-ATR axis in chemoresistance.
Main Methods:
- Utilized gemcitabine-resistant PDAC cell lines and an orthotopic PDAC mouse model.
- Investigated protein degradation pathways, phosphatase activity, and protein complex formation.
- Employed PP2A inhibitor (LB-100) and specific antibodies to disrupt the identified complex.
Main Results:
- Gemcitabine-resistant PDAC cells exhibit CIP2A degradation, leading to increased PP2A activity and cytoplasmic ATR dephosphorylation.
- Dephosphorylated ATR forms a mitochondria-targeted antiapoptotic protein (mtATR), which complexes with tBid, inducing apoptotic dormancy.
- Disruption of the mtATR-tBid complex by LB-100 or an ATR antibody restores apoptosis and inhibits tumor growth in vivo.
Conclusions:
- A novel mechanism of chemoresistance involving CIP2A degradation, PP2A activation, and the formation of a pro-apoptotic complex (mtATR-tBid) was identified in PDAC.
- Targeting the mtATR-tBid complex represents a promising strategy to overcome gemcitabine resistance.
- LB-100 demonstrates efficacy by disrupting this complex, offering a potential therapeutic approach for resistant pancreatic cancer.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
The Intrinsic Apoptotic Pathway
Drugs that Stabilize Microtubules
Negative Regulator Molecules
Anaphase Promoting Complex

